CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in demand for personalized medicines
3.4.1.2. Rise in prevalence of Cancer
3.4.1.3. Rise in prevalence of chronic conditions in the population
3.4.2. Restraints
3.4.2.1. High cost of personalized medicines
3.4.2.2. Lack of awareness regarding personalized medicines among population
3.4.3. Opportunities
3.4.3.1. Increase in healthcare expenditure with improvements in healthcare facilities
3.4.3.2. Technological advancements in personalized medicines
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: PERSONALIZED MEDICINE MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Personalized Medicine Therapeutics
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Personalized Medicine Therapeutics Personalized Medicine Market by Type
4.3. Personalized Medicine Diagnostics
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: PERSONALIZED MEDICINE MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oncology
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Infectious disease
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Neurology or Psychiatry
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Cardiovascular
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Others
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
CHAPTER 6: PERSONALIZED MEDICINE MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals and Clinics
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Others
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: PERSONALIZED MEDICINE MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Product
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Product
7.2.5.1.3. Market size and forecast, by Application
7.2.5.1.4. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Product
7.2.5.2.3. Market size and forecast, by Application
7.2.5.2.4. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Product
7.2.5.3.3. Market size and forecast, by Application
7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Product
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Product
7.3.5.1.3. Market size and forecast, by Application
7.3.5.1.4. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Product
7.3.5.2.3. Market size and forecast, by Application
7.3.5.2.4. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Product
7.3.5.3.3. Market size and forecast, by Application
7.3.5.3.4. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Product
7.3.5.4.3. Market size and forecast, by Application
7.3.5.4.4. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Product
7.3.5.5.3. Market size and forecast, by Application
7.3.5.5.4. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Product
7.3.5.6.3. Market size and forecast, by Application
7.3.5.6.4. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Product
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Product
7.4.5.1.3. Market size and forecast, by Application
7.4.5.1.4. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Product
7.4.5.2.3. Market size and forecast, by Application
7.4.5.2.4. Market size and forecast, by End User
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Product
7.4.5.3.3. Market size and forecast, by Application
7.4.5.3.4. Market size and forecast, by End User
7.4.5.4. Rest of Asia-Pacific
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Product
7.4.5.4.3. Market size and forecast, by Application
7.4.5.4.4. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Product
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Latin America
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Product
7.5.5.1.3. Market size and forecast, by Application
7.5.5.1.4. Market size and forecast, by End User
7.5.5.2. Middle East And Africa
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Product
7.5.5.2.3. Market size and forecast, by Application
7.5.5.2.4. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Abbott Laboratories
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. ARIEL Precision Medicine, Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Key strategic moves and developments
9.3. F. Hoffmann-La Roche Ltd.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. GE Healthcare,Inc
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Aadi Bioscience, Inc.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Illumina, Inc.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. QIAGEN
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Eli Lilly and Company
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Takeda Pharmaceutical Company Ltd
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Abbvie Inc
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
List of Tables
TABLE 01. GLOBAL PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 02. PERSONALIZED MEDICINE MARKET FOR PERSONALIZED MEDICINE THERAPEUTICS, BY REGION, 2021-2031 ($BILLION)
TABLE 03. GLOBAL PERSONALIZED MEDICINE THERAPEUTICS PERSONALIZED MEDICINE MARKET, BY TYPE, 2021-2031 ($BILLION)
TABLE 04. PERSONALIZED MEDICINE MARKET FOR PERSONALIZED MEDICINE DIAGNOSTICS, BY REGION, 2021-2031 ($BILLION)
TABLE 05. GLOBAL PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 06. PERSONALIZED MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021-2031 ($BILLION)
TABLE 07. PERSONALIZED MEDICINE MARKET FOR INFECTIOUS DISEASE, BY REGION, 2021-2031 ($BILLION)
TABLE 08. PERSONALIZED MEDICINE MARKET FOR NEUROLOGY OR PSYCHIATRY, BY REGION, 2021-2031 ($BILLION)
TABLE 09. PERSONALIZED MEDICINE MARKET FOR CARDIOVASCULAR, BY REGION, 2021-2031 ($BILLION)
TABLE 10. PERSONALIZED MEDICINE MARKET FOR OTHERS, BY REGION, 2021-2031 ($BILLION)
TABLE 11. GLOBAL PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 12. PERSONALIZED MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2031 ($BILLION)
TABLE 13. PERSONALIZED MEDICINE MARKET FOR OTHERS, BY REGION, 2021-2031 ($BILLION)
TABLE 14. PERSONALIZED MEDICINE MARKET, BY REGION, 2021-2031 ($BILLION)
TABLE 15. NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 16. NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 17. NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 18. NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)
TABLE 19. U.S. PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 20. U.S. PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 21. U.S. PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 22. CANADA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 23. CANADA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 24. CANADA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 25. MEXICO PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 26. MEXICO PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 27. MEXICO PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 28. EUROPE PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 29. EUROPE PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 30. EUROPE PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 31. EUROPE PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)
TABLE 32. GERMANY PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 33. GERMANY PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 34. GERMANY PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 35. FRANCE PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 36. FRANCE PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 37. FRANCE PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 38. UK PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 39. UK PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 40. UK PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 41. ITALY PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 42. ITALY PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 43. ITALY PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 44. SPAIN PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 45. SPAIN PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 46. SPAIN PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 47. REST OF EUROPE PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 48. REST OF EUROPE PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 49. REST OF EUROPE PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 50. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 51. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 52. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 53. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)
TABLE 54. JAPAN PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 55. JAPAN PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 56. JAPAN PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 57. CHINA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 58. CHINA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 59. CHINA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 60. AUSTRALIA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 61. AUSTRALIA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 62. AUSTRALIA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 63. REST OF ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 64. REST OF ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 65. REST OF ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 66. LAMEA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 67. LAMEA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 68. LAMEA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 69. LAMEA PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)
TABLE 70. LATIN AMERICA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 71. LATIN AMERICA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 72. LATIN AMERICA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 73. MIDDLE EAST AND AFRICA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 74. MIDDLE EAST AND AFRICA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 75. MIDDLE EAST AND AFRICA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 76. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 77. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 78. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 79. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 80. ABBOTT LABORATORIES: KEY STRATEGIES
TABLE 81. ARIEL PRECISION MEDICINE, INC.: KEY EXECUTIVES
TABLE 82. ARIEL PRECISION MEDICINE, INC.: COMPANY SNAPSHOT
TABLE 83. ARIEL PRECISION MEDICINE, INC.: PRODUCT SEGMENTS
TABLE 84. ARIEL PRECISION MEDICINE, INC.: PRODUCT PORTFOLIO
TABLE 85. ARIEL PRECISION MEDICINE, INC.: KEY STRATEGIES
TABLE 86. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 87. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 88. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 89. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 90. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIES
TABLE 91. GE HEALTHCARE,INC: KEY EXECUTIVES
TABLE 92. GE HEALTHCARE,INC: COMPANY SNAPSHOT
TABLE 93. GE HEALTHCARE,INC: PRODUCT SEGMENTS
TABLE 94. GE HEALTHCARE,INC: PRODUCT PORTFOLIO
TABLE 95. GE HEALTHCARE,INC: KEY STRATEGIES
TABLE 96. AADI BIOSCIENCE, INC.: KEY EXECUTIVES
TABLE 97. AADI BIOSCIENCE, INC.: COMPANY SNAPSHOT
TABLE 98. AADI BIOSCIENCE, INC.: PRODUCT SEGMENTS
TABLE 99. AADI BIOSCIENCE, INC.: PRODUCT PORTFOLIO
TABLE 100. AADI BIOSCIENCE, INC.: KEY STRATEGIES
TABLE 101. ILLUMINA, INC.: KEY EXECUTIVES
TABLE 102. ILLUMINA, INC.: COMPANY SNAPSHOT
TABLE 103. ILLUMINA, INC.: PRODUCT SEGMENTS
TABLE 104. ILLUMINA, INC.: PRODUCT PORTFOLIO
TABLE 105. ILLUMINA, INC.: KEY STRATEGIES
TABLE 106. QIAGEN: KEY EXECUTIVES
TABLE 107. QIAGEN: COMPANY SNAPSHOT
TABLE 108. QIAGEN: PRODUCT SEGMENTS
TABLE 109. QIAGEN: PRODUCT PORTFOLIO
TABLE 110. QIAGEN: KEY STRATEGIES
TABLE 111. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 112. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 113. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 114. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 115. TAKEDA PHARMACEUTICAL COMPANY LTD: KEY EXECUTIVES
TABLE 116. TAKEDA PHARMACEUTICAL COMPANY LTD: COMPANY SNAPSHOT
TABLE 117. TAKEDA PHARMACEUTICAL COMPANY LTD: SERVICE SEGMENTS
TABLE 118. TAKEDA PHARMACEUTICAL COMPANY LTD: PRODUCT PORTFOLIO
TABLE 119. ABBVIE INC: KEY EXECUTIVES
TABLE 120. ABBVIE INC: COMPANY SNAPSHOT
TABLE 121. ABBVIE INC: PRODUCT SEGMENTS
TABLE 122. ABBVIE INC: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. PERSONALIZED MEDICINE MARKET, 2021-2031
FIGURE 02. SEGMENTATION OF PERSONALIZED MEDICINE MARKET, 2021-2031
FIGURE 03. TOP INVESTMENT POCKETS IN PERSONALIZED MEDICINE MARKET (2022-2031)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPERSONALIZED MEDICINE MARKET
FIGURE 10. PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR PERSONALIZED MEDICINE THERAPEUTICS, BY COUNTRY 2021 AND 2031(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR PERSONALIZED MEDICINE DIAGNOSTICS, BY COUNTRY 2021 AND 2031(%)
FIGURE 13. PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY 2021 AND 2031(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR INFECTIOUS DISEASE, BY COUNTRY 2021 AND 2031(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR NEUROLOGY OR PSYCHIATRY, BY COUNTRY 2021 AND 2031(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR CARDIOVASCULAR, BY COUNTRY 2021 AND 2031(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
FIGURE 19. PERSONALIZED MEDICINE MARKET, BY END USER, 2021(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2021 AND 2031(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
FIGURE 22. PERSONALIZED MEDICINE MARKET BY REGION, 2021
FIGURE 23. U.S. PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
FIGURE 24. CANADA PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
FIGURE 25. MEXICO PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
FIGURE 26. GERMANY PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
FIGURE 27. FRANCE PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
FIGURE 28. UK PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
FIGURE 29. ITALY PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
FIGURE 30. SPAIN PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
FIGURE 31. REST OF EUROPE PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
FIGURE 32. JAPAN PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
FIGURE 33. CHINA PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
FIGURE 34. AUSTRALIA PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
FIGURE 35. REST OF ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
FIGURE 36. LATIN AMERICA PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
FIGURE 37. MIDDLE EAST AND AFRICA PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
FIGURE 38. TOP WINNING STRATEGIES, BY YEAR
FIGURE 39. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 40. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 41. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 42. COMPETITIVE DASHBOARD
FIGURE 43. COMPETITIVE HEATMAP: PERSONALIZED MEDICINE MARKET
FIGURE 44. TOP PLAYER POSITIONING, 2021
FIGURE 45. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
FIGURE 46. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 47. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 48. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)
FIGURE 49. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 50. GE HEALTHCARE,INC: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 51. GE HEALTHCARE,INC: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 52. GE HEALTHCARE,INC: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 53. AADI BIOSCIENCE, INC.: NET REVENUE, 2020-2021 ($MILLION)
FIGURE 54. ILLUMINA, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 55. ILLUMINA, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 56. ILLUMINA, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 57. QIAGEN: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 58. QIAGEN: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 59. QIAGEN: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 60. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 61. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 62. TAKEDA PHARMACEUTICAL COMPANY LTD: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 63. TAKEDA PHARMACEUTICAL COMPANY LTD: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 64. ABBVIE INC: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 65. ABBVIE INC: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 66. ABBVIE INC: REVENUE SHARE BY REGION, 2021 (%)